000			03550nam a22003375i 4500
999			_c399096 _d399096
001			399096
003			ES-MaUEC
005			20240322092445.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			230316s2023 sz | o |||| 0|eng d
020			_a9783031210549
024	7		_a10.1007/978-3-031-21054-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQP356.3 _b2023 EB
245	0	0	_aDrug Development in Psychiatry _cedited by Matthew Macaluso, Sheldon H Preskorn, Richard C Shelton
250			_a1st ed. 2023.
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aAdvances in Neurobiology _x2190-5223 _v30
505	0		_aDrug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development -- The History of Drug Development in Psychiatry: A Lesson in Serendipity -- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders -- Discovery and Development of Monoamine Transporter Ligands -- Drug Development for New Psychiatric Drug Therapies -- Post-Approval Research in Drug Development: Priorities and Practices -- Discovery of new transmitter systems and hence new drug targets -- Reverse engineering drugs -- Back to the Future of Neuropsychopharmacology -- Targeted Treatments for Fragile X Syndrome -- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders Diseases -- Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics -- The role of fMRI in drug development: an update -- Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example -- Genomics in Treatment Development -- Increased Inflammation and Treatment of Depression: from Resistance to Reuse, Repurposing and Redesign -- Experimental medicine approaches in early phase CNS drug development.
520			_aThis new book reviews clinical trial methodology as it pertains to drug development in psychiatry. The authors will describe the process of drug development in psychiatry from discovery through marketing with the help of clinically relevant examples. The history of drug development in psychiatry is explored dating back to the era of serendipitous discovery and culminating in an era of new and highly focused targets. The book will delineate how drug development in psychiatry has changed and adapted with the discovery of drugs with novel mechanisms of action. Drug Development in Psychiatry elucidates how biomarkers, genetics, and advances in neuroscience and neuroimaging have influenced drug development approaches, which will ultimately change the practice of psychiatry. The book charts the early years of drug discovery by chance observation, reviews the developments of the past 50 years of refined targeting of CNS drugs without the discovery of mechanistically new drugs, and looks to the discovery of mechanistically new drugs, the examination of new targets, genetics, and biomarkers.
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9146728 _aNeuroquímica
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-21054-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b03/2024 _dz _ek _zSI